TOKYO & RAVENSBURG, Germany--(BUSINESS WIRE)--Vetter, one of the global leaders in the aseptic manufacturing of drug-delivery systems, servicing the top-ten pharma/biotech companies worldwide along with mid-size firms and emerging startups, today announced the opening of a new business entity in Tokyo, Japan. The announcement was made at a ceremony attended by executives of customer and partner companies with a presence in the Asian region, as well as Vetter and industry executives. Mr. Hiroaki Suzuki in his role as Business Development Manager for Vetter Pharma International Japan K.K., will lead Vetter’s business activities in Japan, reporting to Ms. Chervee Ho based in Singapore in her role as Director Key Account Management Asia Pacific.
The new office underlines the importance of Japan for Vetter’s business activities. As the second largest pharmaceutical single market, Japan is home to a number of leading global companies which offer a promising injectable pipeline. It is also a point of departure for several established Japanese companies for increasing their global reach. As such, the new office will support customer relations and aid in the development of new business within Japan, while strengthening the global position of Vetter, particularly in selected Asia Pacific markets. As a strategic partner, Vetter supports its worldwide clients through every phase of their drug product’s lifecycle, from early product development to launch to commercial supply.
“For more than 35 years, the name Vetter has been synonymous with high-quality aseptically prefilled drug-delivery systems. With our office opening in Japan, we continue to build upon that history with a further demonstration of our strategy to better service the needs of our growing customer base worldwide, including Asia,” said Udo J. Vetter, Chairman of the Advisory Board and member of the owner family.
“Our presence in Japan will help to increase awareness of Vetter’s services in this growing healthcare market by presenting our expertise and market position onsite,” added Managing Director Peter Soelkner. “Following the creation of our Asia Pacific hub in Singapore last year, the new office is a further development, establishing a dedicated presence in the most important single market of the region. This activity affords us the opportunity to strengthen personal contacts with national audiences.”
“Vetter’s decision to expand their presence in the Asia Pacific region and to open their first office in Japan is a strong message of their commitment to service the needs of this important market,” said Dr. Hitoshi Kuboniwa, Senior Vice President and General Manager of Pharmaceutical Technology Division at Chugai Pharmaceutical Co., Ltd. “As a trusted partner, we appreciate that step, wishing Vetter as a company in general, and Ms. Ho and Mr. Suzuki in particular, a promising start for their onsite activities in Japan.”
The new office is located in district Shinagawa, which is one of the 23 wards of Tokyo, and a rapidly developing area. Situated on the 28th floor of a business tower directly across from Shinagawa station, being one of the transportation hubs in Tokyo, the office offers ease of accessibility for many JR Rail lines with proximity to international Haneda and Narita airport through direct train connections.
Left to right: Dr. Hitoshi Kuboniwa (Senior Vice President and General Manager of Pharmaceutical Technology Division at Chugai Pharmaceutical Co., Ltd.) and Peter Soelkner (Managing Director Vetter) share in the cutting of the ribbon signaling the opening of the Vetter Pharma International Japan K.K. office, its second in the Asia Pacific region.
About Vetter
Vetter is a premier contract development and manufacturing organization (CDMO) and a global leader in the fill and finish of aseptically prefilled syringe systems, cartridges and vials. Headquartered in Ravensburg, Germany, with facilities in Germany and the United States, the company provides state-of-the-art manufacturing, from early clinical development through commercial filling and packaging of parenteral drugs. The CDMO’s extensive experience covers a broad range of complex compounds, including monoclonal antibodies, peptides and interferons. Vetter supports its customers every step of the way, guiding their products through development, regulatory approval, launch and lifecycle management. Known for quality, the company offers a foundation of experience spanning more than 35 years, including dozens of product approvals for novel bio/ pharmaceutical compounds. Since 2014, Vetter operates a representative office in Singapore, increasing the presence of the company and the awareness of its service portfolio in the Asian healthcare market. Visit www.vetter-pharma.com
